|
|
|
SNY Forecast
Recent SNY Price |
|
SNY Forecast Price |
$50.03 |
+21.33% |
$60.70 |
As of 2024-05-02
Recent SNY Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
9 |
9 |
8 |
8 |
Buy ratings: |
0 |
0 |
0 |
0 |
Hold ratings: |
3 |
3 |
2 |
2 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
1 |
1 |
1 |
1 |
Average rating: |
1.77 |
1.77 |
1.73 |
1.73 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the Sanofi forecast (traded under symbol SNY) for one year forward price target at the top of this page, we have presented the average SNY forecast for forward target price across the 5 analysts covering SNY, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median SNY forecast price target (median being the middle where half of analysts had a higher SNY forecast and half had a lower SNY forecast, which is a different metric than the average or mean) was $61.5 as of 2024-05-02, while the
highest SNY forecast in the analyst group was $67.0, and the lowest SNY forecast in the analyst group was
$55.0, with a standard deviation of $5.563. Get the latest Zacks research report on SNY — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
|
|
|
Quotes delayed 20 minutes
|
Buy (3.23 out of 4)
45th percentile
|
PARTNER NEWS:Fri, Apr 26, 9:34 AM, Zacks
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Thu, Apr 25, 11:47 AM, Zacks
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
|
|